Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewML 385 is an Nrf2 inhibitor. Blocks Nrf2 downstream target gene expression. Enhances cytotoxic effects of doxorubicin (Cat. No. 2252) or Taxol (Cat. No. 1097) in non-small cell lung cancer (NSCLC). Demonstrates selectivity for NSCLC cells with KEAP1 mutations.
ML 385 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 511.59 |
Formula | C29H25N3O4S |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
CAS Number | 846557-71-9 |
PubChem ID | 1383822 |
InChI Key | LINHYWKZVCNAMQ-UHFFFAOYSA-N |
Smiles | CC1=C(C2=CC=C3N(C(C4=C(C=CC=C4)C)=O)CCC3=C2)N=C(S1)NC(CC5=CC=C6OCOC6=C5)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 25.58 | 50 |
The following data is based on the product molecular weight 511.59. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.5 mM | 3.91 mL | 19.55 mL | 39.09 mL |
2.5 mM | 0.78 mL | 3.91 mL | 7.82 mL |
5 mM | 0.39 mL | 1.95 mL | 3.91 mL |
25 mM | 0.08 mL | 0.39 mL | 0.78 mL |
References are publications that support the biological activity of the product.
Singh et al (2016) Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors. ACS Chem.Biol. 11 3214 PMID: 27552339
If you know of a relevant reference for ML 385, please let us know.
Keywords: ML 385, ML 385 supplier, ML385, Nrf2, snhibitors, cytotoxic, non-small, cell, lung, cancer, NSCLC, phenotypically, lethal, 6243, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for ML 385 include:
Jeong Hwan et al (2020) Capsosiphon fulvescens Glycoproteins Enhance Probiotics-Induced Cognitive Improvement in Aged Rats. Nutrients 12 PMID: 32245093
Steven C et al (2023) Identifying new biomarkers of aggressive Group 3 and SHH medulloblastoma using 3D hydrogel models, single cell RNA sequencing and 3D OrbiSIMS imaging. Acta Neuropathol Commun 11 6 PMID: 36631900
Do you know of a great paper that uses ML 385 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review ML 385 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.